Therapeutic Solutions International (Therapeutic Solutions International) EBIT : $-1.80 Mil (TTM As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Therapeutic Solutions International EBIT?

Therapeutic Solutions International's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-0.38 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.80 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Therapeutic Solutions International's annualized ROC % for the quarter that ended in Dec. 2023 was -52.36%. Therapeutic Solutions International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -303.67%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Therapeutic Solutions International's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -52.94%.

Therapeutic Solutions International EBIT Historical Data

The historical data trend for Therapeutic Solutions International's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Therapeutic Solutions International EBIT Chart

Therapeutic Solutions International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-1.35

-1.90

-2.35

-3.23

-1.80

Therapeutic Solutions International Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-1.01	-0.46	-0.44	-0.52	-0.38

Competitive Comparison of Therapeutic Solutions International's EBIT

For the Biotechnology subindustry, Therapeutic Solutions International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Therapeutic Solutions International's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Therapeutic Solutions International's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Therapeutic Solutions International's EV-to-EBIT falls into.

Therapeutic Solutions International EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.80 Mil.

Therapeutic Solutions International (OTCPK:TSOI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Therapeutic Solutions International's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-2.228 * ( 1 - -0.21% )	/	( (4.363	+	4.165)	/ 2 )
=	-2.2326788	/	4.264
=	-52.36 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3.474	-	0.983	-	( 0.09	-	max(0, 2.053	-	0.181	+	0.09	))
=	4.363

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3.292	-	0.941	-	( 0.028	-	max(0, 1.9	-	0.086	+	0.028	))
=	4.165

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Therapeutic Solutions International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.532	/	( ( (0.509 + max(-1.185, 0))	+	(0.5 + max(-1.064, 0)) )	/	2 )
=	-1.532	/	( ( 0.509	+	0.5 )	/	2 )
=	-1.532	/	0.5045
=	-303.67 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.022	+	0.026	+	0.043)	-	(0.983	+	0	+	0.293)
=	-1.185

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.019	+	0.023	+	0.016)	-	(0.941	+	0	+	0.181)
=	-1.064

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Therapeutic Solutions International's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-1.799	/	3.398
	=	-52.94 %

Therapeutic Solutions International EBIT Related Terms

Thank you for viewing the detailed overview of Therapeutic Solutions International's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Therapeutic Solutions International (Therapeutic Solutions International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Therapeutic Solutions International Inc (OTCPK:TSOI) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

701 Wild Rose Lane, Elk City, ID, USA, 83525

Website

https://www.therapeuticsolutionsint.com

Therapeutic Solutions International Inc focuses on immune modulation for the treatment of several specific diseases. It is engaged in developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. The business divisions of the company are Nutraceutical Division which produces nutraceuticals. Its current product, QuadraMune, is a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone. Cellular Division obtained exclusive rights to a patented adult stem cell for the development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).

Executives

Thomas Ichim	director	211 E. OSBORN RD, PHOENIX AZ 85012
Gerry B Berg	officer: CFO	1658 AVENIDA LA POSTA, ENCINITAS CA 92024
Timothy G Dixon	director, officer: Chairman, President, CEO	4093 OCEANSIDE BLVD., SUITE B, OCEANSIDE CA 92056
Barry Glassman	officer: VP, Training & Education	2051 ELBOW LANE, ALLENTOWN PA 18103
James P Boyd	director, 10 percent owner	PO BOX 2145, RANCHO SANTA FE CA 92067